A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
ABT-888
CNS tumors
DIPG
PARP inhibition
veliparib
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
09 06 2020
09 06 2020
Historique:
pubmed:
6
2
2020
medline:
28
4
2021
entrez:
4
2
2020
Statut:
ppublish
Résumé
A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series. Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg/m2 b.i.d. and TMZ 135 mg/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity. Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n = 1), grade 3 maculopapular rash (n = 2), and grade 3 nervous system disorder (generalized neurologic deterioration) (n = 1). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively. Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG. NCT01514201.
Sections du résumé
BACKGROUND
A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series.
METHODS
Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg/m2 b.i.d. and TMZ 135 mg/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity.
RESULTS
Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n = 1), grade 3 maculopapular rash (n = 2), and grade 3 nervous system disorder (generalized neurologic deterioration) (n = 1). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively.
CONCLUSION
Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG.
TRIAL REGISTRATION
NCT01514201.
Identifiants
pubmed: 32009149
pii: 5721145
doi: 10.1093/neuonc/noaa016
pmc: PMC7283021
doi:
Substances chimiques
Benzimidazoles
0
veliparib
01O4K0631N
Temozolomide
YF1K15M17Y
Banques de données
ClinicalTrials.gov
['NCT01514201']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
875-885Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA081457
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Neurooncol. 2015 Apr;122(2):409-17
pubmed: 25682091
AJNR Am J Neuroradiol. 2017 Jan;38(1):170-175
pubmed: 27633807
Neuro Oncol. 2011 Aug;13(8):904-9
pubmed: 21757444
Neuro Oncol. 2014 Dec;16(12):1661-8
pubmed: 24908656
Oncogene. 2015 Jun;34(26):3349-56
pubmed: 25220415
Mol Cancer Ther. 2015 Nov;14(11):2560-8
pubmed: 26351319
J Clin Oncol. 2010 Mar 10;28(8):1337-44
pubmed: 20142589
J Clin Oncol. 2015 Apr 20;33(12):1397-406
pubmed: 25779564
Neuro Oncol. 2011 Apr;13(4):417-27
pubmed: 21297126
Clin Trials. 2005;2(6):467-78
pubmed: 16422307
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Cancer Chemother Pharmacol. 2010 Feb;65(3):419-25
pubmed: 19526240
Neuro Oncol. 2016 May;18(5):725-34
pubmed: 26487690
Cancer Res. 2014 Jul 15;74(14):3716-26
pubmed: 24812271
Cancer Treat Rev. 2012 Feb;38(1):27-35
pubmed: 21764221
Nat Rev Cancer. 2010 Apr;10(4):293-301
pubmed: 20200537
J Neurosurg Pediatr. 2016 Oct;18(4):396-407
pubmed: 27314542
Clin Cancer Res. 2007 May 1;13(9):2728-37
pubmed: 17473206
Ann Oncol. 2018 Jan 1;29(1):154-161
pubmed: 29045554
Neuroradiology. 2014 May;56(5):405-12
pubmed: 24626721
J Transl Med. 2017 Mar 17;15(1):61
pubmed: 28314386
Neoplasia. 2016 Feb;18(2):82-9
pubmed: 26936394
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Neuro Oncol. 2018 Oct 9;20(11):1547-1555
pubmed: 29741745
Neurosurgery. 2007 Jun;60(6):E1148-9; discussion E1149
pubmed: 17538362
Clin Pharmacokinet. 2014 May;53(5):479-88
pubmed: 24452810
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Neuro Oncol. 2011 Nov;13(11):1171-7
pubmed: 21849329
Anal Biochem. 2008 Oct 15;381(2):240-7
pubmed: 18674509
Future Oncol. 2016 Jun;12(12):1439-56
pubmed: 27087632
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
J Natl Cancer Inst. 2015 Nov 27;108(5):
pubmed: 26615020
Clin Cancer Res. 2007 May 15;13(10):3033-42
pubmed: 17505006
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Neuro Oncol. 2011 Apr;13(4):410-6
pubmed: 21345842
Nat Med. 2011 Jun 26;17(7):875-82
pubmed: 21706030
Oncotarget. 2011 Dec;2(12):984-96
pubmed: 22184287
Semin Radiat Oncol. 2010 Oct;20(4):274-81
pubmed: 20832020
PLoS One. 2011;6(10):e26152
pubmed: 22028822
Clin Cancer Res. 2008 Apr 15;14(8):2378-86
pubmed: 18413828
Mol Oncol. 2016 May;10(5):751-63
pubmed: 26794465
Int J Biol Sci. 2017 Feb 17;13(2):198-208
pubmed: 28255272
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
pubmed: 21300883
Radiat Oncol. 2013 Mar 19;8:65
pubmed: 23510353